MTOR and colonic neoplasm: The results obtained by He et al. (2016) regarding the use of high concentrations of everolimus (10-25 μM) in colon cancer cells with the BRAF V600E and K-RAS mutation showed that they are unlikely to respond to monotherapy targeting mTOR inhibitor, but might benefit from combination therapy with PI3K, RAF or MEK inhibitors.